A growing number of clinicians rely on AdaptDx to detect age-related macular degeneration in their adult patients. Our customers tell the story of how they’re fighting against blindness caused by AMD.
I have made performing an AdaptDx test on all my patients that are over the age of 60 years old my standard of care. I have found that about 40% fail the rapid test, even when the macula looks perfect clinically. This has helped me to be able to begin proactive measures with patients that previously would have been overlooked until there was more advanced disease.
There is a “Tidal Wave” of effects that accompany legal blindness from AMD- depression, loss of independence, inability to maintain your home, inability to drive or read, inability to work, social isolation, disinterest in previous hobbies, etc. The AdaptDx helps doctors give their patients guidance on how to lower the risk of blindness from AMD and to maintain a better quality of life.
After five years of using the AdaptDx to identify AMD at its earliest stage and then placing patients on a treatment regimen involving modifiable risk factors, I have documented many patients having improved Rod Intercept times (improved dark adaptation) and maintaining their visual acuity.
I feel that the AdaptDx instrument from MacuLogix is the most significant diagnostic breakthrough in my career! We finally have an instrument that helps us diagnose AMD before vision loss occurs!
When I look at the future of managing macular degeneration, I see the AdaptDx as the essential tool in AMD management just as now I see the OCT as the essential tool in managing glaucoma in its earliest stages. By finding a disease early, and intervening appropriately we have the best chance of altering the course.